60 Degrees Pharmaceuticals exercises license option for castanospermine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
January 28, 2026 8:01 AM ESTWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60 Degrees Pharma or the Company), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it has exercised the option in its agreement with Florida State University (FSU) to negotiate an exclusive license to use large-scale purification techniques to extract castanospermine from the seeds of Castanospermum australe... More
